The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice

Arthritis and Rheumatism

Volumn 63, Issue 4, 2011, Pages 1076-1085

  Sekine, Hideharu ^a   Hsieh Kinser, Ting Ting ^a   Qiao, Fei ^a   Martinez, Efrain ^a   Paulling, Emily ^a   Ruiz, Phillip ^b   Gilkeson, Gary S ^a   Tomlinson, Stephen ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AUTOANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; CR2 CRRY; CR2 FH; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN; SOLUBLE CR2; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNITY; CLINICAL EVALUATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS; HISTOPATHOLOGY; IMMUNOMODULATION; INTERSTITIAL NEPHRITIS; KIDNEY; LUPUS ERYTHEMATOSUS NEPHRITIS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL; TREATMENT DURATION; URINARY EXCRETION; VASCULITIS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGEN-ANTIBODY COMPLEX; AUTOIMMUNITY; COMPLEMENT C1Q; COMPLEMENT C3; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, ALTERNATIVE; DISEASE MODELS, ANIMAL; DNA; FEMALE; IMMUNOGLOBULIN G; KIDNEY; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; RECOMBINANT FUSION PROTEINS;

EID: 79953729061     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30222     Document Type: Article

References (45)

1. Bao L, Quigg RJ. Complement in lupus nephritis: the good, the bad, and the unknown. Semin Nephrol 2007;27:69-80.
2. Sekine H, Watanabe H, Gilkeson GS. Enrichment of antiglomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice. J Immunol 2004;172:3913-21. (Pubitemid 38337979)
3. Kotzin BL. Systemic lupus erythematosus. Cell 1996;85:303-6. (Pubitemid 26160701)
4. Walport MJ. Complement: first of two parts. N Engl J Med 2001;344:1058-66.
5. Botto M, Walport MJ. Hereditary deficiency of C3 in animals and humans. Int Rev Immunol 1993;10:37-50.
6. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000;76:227-324.
7. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19:56-9. (Pubitemid 28242023)
8. Mitchell DA, Pickering MC, Warren J, Fossati-Jimack L, Cortes- Hernandez J, Cook HT, et al. C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol 2002;168:2538-43. (Pubitemid 34171862)
9. Einav S, Pozdnyakova OO, Ma M, Carroll MC. Complement C4 is protective for lupus disease independent of C3. J Immunol 2002; 168:1036-41. (Pubitemid 34094466)
10. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004;22:431-56. (Pubitemid 38680429)
11. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun 2010;34:J276-86.
12. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985;37:269-390. (Pubitemid 15093080)
13. Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, et al. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 2000;164:786-94. (Pubitemid 30043702)
14. Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int 2004;65:129-38. (Pubitemid 38037497)
15. Quigg RJ, Kozono Y, Berthiaume D, Lim A, Salant DJ, Weinfeld A, et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol 1998; 160:4553-60. (Pubitemid 28217315)
16. Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S. Low-ose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 2008;180:1231-8.
17. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 1996;93: 8563-8. (Pubitemid 26269599)
18. Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001;166:6444-51. (Pubitemid 32440780)
19. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 2008;181:8068-76.
20. Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, et al. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 2005;115:2444-53. (Pubitemid 41266206)
21. Sekine H, Graham KL, Zhao S, Elliott MK, Ruiz P, Utz PJ, et al. Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus. J Immunol 2006;177:7423-34. (Pubitemid 44715113)
22. Shivakumar S, Tsokos GC, Datta SK. T cell receptor α/β expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989;143:103-12. (Pubitemid 19174206)
23. Fischer MB, Ma M, Goerg S, Zhou X, Xia J, Finco O, et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 1996;157:549-56. (Pubitemid 26231355)
24. Lefkowith JB, Gilkeson GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies [review]. Arthritis Rheum 1996;39:894-903. (Pubitemid 26182056)
25. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, et al. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J Exp Med 1978;148:1198-215. (Pubitemid 9053639)
26. Pankewycz OG, Migliorini P, Madaio MP. Polyreactive autoantibodies are nephritogenic in murine lupus nephritis. J Immunol 1987;139:3287-94. (Pubitemid 18021979)
27. Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus: association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977;59:90-6. (Pubitemid 8018043)
28. Nose M, Nishimura M, Ito MR, Toh J, Shibata T, Sugisaki T. Arteritis in a novel congenic strain of mice derived from MRL/Lpr lupus mice: genetic dissociation from glomerulonephritis and limited autoantibody production. Am J Pathol 1996;149:1763-9. (Pubitemid 26363981)
29. Kim YU, Kinoshita T, Molina H, Hourcade D, Seya T, Wagner LM, et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med 1995;181:151-9.
30. DiScipio R. In: Morley BJ, Walport MJ, editors. The complement facts book. Academic Press, London; 2000. p. 168-73.
31. Whaley K. Complement and immune complex diseases. In: Whaley K, editor. Complement in health and disease. Norwell (MA): MTP Press; 1987. p. 163-83.
32. Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, et al. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol 2003;14:670-9. (Pubitemid 36246011)
33. Holers VM, Boackle SA. Complement receptor 2 and autoimmunity. Curr Dir Autoimmun 2004;7:33-48.
34. Boackle SA, Culhane KK, Brown JM, Haas M, Bao L, Quigg RJ, et al. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE. Autoimmunity 2004;37:111-23. (Pubitemid 38594275)
35. Boackle SA, Holers VM, Chen X, Szakonyi G, Karp DR, Wakeland EK, et al. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 2001;15:775-85. (Pubitemid 34008505)
36. Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, et al. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-α a potential role in systemic lupus erythematosus. J Immunol 2006;177:383-94. (Pubitemid 43939150)
37. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003;197: 777-88. (Pubitemid 36350872)
38. Crow MK, Kirou KA. Interferon-α in systemic lupus erythematosus. Curr Opin Rheumatol 2004;16:541-7.
39. Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004;173:2134-42. (Pubitemid 38971652)
40. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus: comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992;35:1028-37.
41. Buyon JP, Tamerius J, Ordorica S, Young B, Abramson SB. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum 1992;35:55-61.
42. Wyatt RJ, McAdams AJ, Forristal J, Snyder J, West CD. Glomerular deposition of complement-control proteins in acute and chronic glomerulonephritis. Kidney Int 1979;16:505-12. (Pubitemid 10195861)
43. Wilson MR, Arroyave CM, Nakamura RM, Vaughan JH, Tan EM. Activation of the alternative complement pathway in systemic lupus erythematosus. Clin Exp Immunol 1976;26:11-20.
44. Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008;40:204-10. (Pubitemid 351171405)
45. Cunninghame Graham DS, Vyse TJ. The candidate gene approach: have murine models informed the study of human SLE? Clin Exp Immunol 2004;137:1-7. (Pubitemid 38869770)